Table 1.
Baseline Characteristics of Study Participants
| Characteristics | Intervention group (n = 28) | Control group (n = 36) | All (n = 56)a |
|---|---|---|---|
| Mean (SD) age, years | 53.6 (11.2) | 55.7 (8.4) | 54.4 (9.5) |
| Race | |||
| Black, n (%) | 21 (75.0) | 24 (66.7) | 38 (67.9) |
| White, n (%) | 5 (17.9) | 10 (27.8) | 15 (26.8) |
| Hispanic, n (%) | 2 (7.1) | 2 (5.6) | 3 (5.4) |
| Male gender, n (%) | 27 (96.4) | 35 (97.2) | 55 (9.8) |
| CD4+ count (cells/mm3) | |||
| Mean (SD) | 410.7 (241.6) | 388.0 (218.5) | 409.5 (225.6) |
| Median | 410 | 383 | 394 |
| HIV RNA ≤400 copies/mL, n (%) | 18 (64.3) | 24 (66.7) | 38 (67.9) |
| Type of current ARV therapy | |||
| NNRTI-based regimen, n (%) | 4 (19.0) | 6 (19.3) | 10b (20.8) |
| PI-based regimen, n (%) | 2 (9.5) | 3 (9.7) | 3b (6.2) |
| Boosted PI-based regimen, n (%) | 13 (61.9) | 13 (41.9) | 24b (50.0) |
| Other, n (%) | 2 (9.5) | 9 (29.0) | 11b (22.9) |
| Coinfection with HCV, n (%) | 17 (60.7) | 22 (61.1) | 33 (58.9) |
a
Eight patients participated in both the intervention group and the control group.
b
Some patients were not taking any ARV medication (total of 8).
ARV, antiretroviral; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; HCV, hepatitis C virus; SD, standard deviation.